News
FDA set to unveil new Covid vax guidelines today
While details of the guidance remain closely held, some clues are likely found in the FDA’s late Friday letter approving Novavax’s Covid vaccine. Who can get it: The license covers a limited population — adults 65 and older and people ages 12 to 64 with at least one underlying condition putting them at high risk for severe disease — compared with the two messenger RNA shots available for Covid recommended for all people 12 and older.
Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.
Novavax shares jumped more than 15% on Monday after the company secured a long-awaited U.S. regulatory approval for its COVID ...
The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by ...
"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...
The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.
In the NEJM article, the FDA notes that covid booster uptake has been low in the US, with less than a quarter of people ...
The agency will narrow its approval for updated coronavirus vaccines, marking a significant shift in the agency’s approach to ...
After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...
WASHINGTON — Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback